-
公开(公告)号：EP2274008B1
公开(公告)日：2014-02-26
申请号：EP09724060.0
申请日：2009-03-27
申请人： ZymoGenetics, Inc.
发明人： SIVAKUMAR, Pallavur V. , GILBERTSON, Debra G. , SNAVELY, Marshall D. , MABRY, George R. , YI, Eugene C. , YAO, Yue , PRESNELL, Scott R.
IPC分类号： A61K39/395 , A61P35/00 , C07K16/22 , C07K16/28
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92
摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443; LCDR2 has the amino acid sequence shown in SEQ ID NO: 434; LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444; HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445; HCDR2 has the amino acid sequence shown in SEQ ID NO: 437; HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442
-
公开(公告)号：EP2274008A2
公开(公告)日：2011-01-19
申请号：EP09724060.0
申请日：2009-03-27
申请人： ZymoGenetics, Inc.
发明人： SIVAKUMAR, Pallavur, V. , GILBERTSON, Debra, G. , SNAVELY, Marshall, D. , MABRY, George, R. , YI, Eugene, C. , YAO, Yue , PRESNELL, Scott, R.
IPC分类号： A61K39/395 , A61P35/00 , C07K16/22 , C07K16/28
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92
摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443; LCDR2 has the amino acid sequence shown in SEQ ID NO: 434; LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444; HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445; HCDR2 has the amino acid sequence shown in SEQ ID NO: 437; HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442
-
公开(公告)号：EP1924603A2
公开(公告)日：2008-05-28
申请号：EP06814491.4
申请日：2006-09-13
申请人： Zymogenetics, Inc.
发明人： THOMPSON, Penny, J. , SIADAK, Anthony, W. , NORIEGA, Claire, R. , FRANKLIN, Henry, R. , OGUZ, Secil , THOMPSON, Deborah, L. , TOPOUZIS, Stavros , FRUEBIS, Joachim , BRASEL, Kenneth , YAO, Yue
IPC分类号： C07K16/18 , C07K14/47 , A61K39/395
CPC分类号： C07K14/4702 , A61K2039/505 , C07K16/22 , C07K2317/76
摘要： The present invention provides methods of using PROK2 and PROK1 antagonist, including monoclonal antibodies to treat inflammation, angiogenesis, and cancer.
-
公开(公告)号：EP1237921A1
公开(公告)日：2002-09-11
申请号：EP00973811.3
申请日：2000-10-23
申请人： ZymoGenetics, Inc.
发明人： XU, Wenfeng , LOFTON-DAY, Catherine, E. , HENNE, Randall , PRESNELL, Scott, R. , YAO, Yue , NOVAK, Julia, E. , FOSTER, Donald, C. , YEE, David, P.
CPC分类号： C07K14/7151
摘要： Novel secreted and membrane bound tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligands, agonists and antagonist. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate inflammation, tumor growth and metastasis, infection, immunity, and cellular maturation.
-
5.发明公开METHODS OF TREATING PAIN AND INFLAMMATION IN NEURONAL TISSUE USING IL-31RA AND OSMRB ANTAGONISTS 审中-公开METHOD FOR疼痛和炎症IN A组织神经的治疗中使用的IL-31RA- AND OSMRB拮抗剂
公开(公告)号：EP2001906A2
公开(公告)日：2008-12-17
申请号：EP07777559.1
申请日：2007-01-16
申请人： Zymogenetics, Inc.
发明人： YAO, Yue , BILSBOROUGH, Janine , KRESJA, Cecile , ZUCKERMAN, Linda , ROGGE, Mark
IPC分类号： C07K16/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： There is provided an isolated monoclonal antibody or binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, for use in the treatment of inflammation in neuronal tissue in a mammal.
-
6.发明公开METHODS OF TREATING PAIN AND INFLAMMATION IN NEURONAL TISSUE USING IL-31 ANTAGONISTS 审中-公开METHOD FOR疼痛和炎症IN A组织神经的治疗中使用的IL-3拮抗剂
公开(公告)号：EP1991581A2
公开(公告)日：2008-11-19
申请号：EP07811781.9
申请日：2007-01-10
申请人： Zymogenetics, Inc.
发明人： YAO, Yue , BILSBOROUGH, Janine , KREJSA, Cecile , ZUCKERMAN, Linda , ROGGE, Mark
IPC分类号： C07K16/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： There is provided an isolated monoclonal antibody or binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, for use in the treatment of inflammation in neuronal tissue in a mammal.
-
公开(公告)号：EP1359938B1
公开(公告)日：2011-03-16
申请号：EP02760986.6
申请日：2002-01-24
申请人： ZymoGenetics, Inc.
IPC分类号： A61K39/395
CPC分类号： C07K14/54 , A61K39/00 , A61K2039/505 , C07K14/705 , C12N15/113 , C12N2310/14
摘要： A method for treating psoriasis. An antagonist to IL-17Dβ9(IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5).
-
8.发明公开METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA 审中-公开USE IL-31的作者呼吸超敏反应和哮喘的处理方法
公开(公告)号：EP2061496A2
公开(公告)日：2009-05-27
申请号：EP08727563.2
申请日：2008-01-10
申请人： Zymogenetics, Inc.
发明人： BILSBOROUGH, Janine , BORT, Susan, J. , CHADWICK, Eric, M. , MUDRI, Sherri, L. , YAO, Yue , BANNINK, Kenneth, M. , MEEHAN, Woerner, P. , REN, Hong Ping
CPC分类号： A61K38/20 , Y02A50/473
摘要： Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
-
公开(公告)号：EP1359938A2
公开(公告)日：2003-11-12
申请号：EP02760986.6
申请日：2002-01-24
申请人： ZymoGenetics, Inc.
IPC分类号： A61K39/395
CPC分类号： C07K14/54 , A61K39/00 , A61K2039/505 , C07K14/705 , C12N15/113 , C12N2310/14
摘要： A method for treating psoriasis. An antagonist to IL-17Dβ9(IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5).
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.031 秒)
